MCIM
NKTR icon

Meadow Creek Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Meadow Creek Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$446K Buy
1,632
+230
+16% +$84.3K 0.01% 761
2019
Q2 		$748K Sell
1,402
-480
-26% -$241K 0.01% 573
2019
Q1 		$948K Sell
1,882
-4,476
-70% -$2.65M 0.02% 479
2018
Q4 		$3.13M Buy
6,358
+1,211
+24% +$731K 0.07% 250
2018
Q3 		$4.71M Buy
5,147
+4,554
+768% +$3.89M 0.09% 206
2018
Q2 		$434K Buy
593
+404
+214% +$466K 0.01% 703
2018
Q1 		$302K Sell
189
-817
-81% -$1.05M 0.01% 843
2017
Q4 		$901K Buy
1,006
+171
+20% +$101K 0.02% 478
2017
Q3 		$300K Buy
835
+113
+16% +$35.3K 0.01% 781
2017
Q2 		$212K Buy
722
+311
+76% +$89.9K 0.01% 861
2017
Q1 		$145K Buy
411
+41
+11% +$9.22K ﹤0.01% 819
2016
Q4 		$68K Buy
+370
New +$75.2K ﹤0.01% 1041

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meadow Creek Investment Management's NKTR Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Nektar Therapeutics (NKTR) stake by 16% in Q3 2019, buying an estimated $84.3K and bringing the position to 1,632 shares worth $446K. The position accounts for 0.01% of the portfolio, ranked #761.

Meadow Creek Investment Management first reported a position in NKTR in Q4 2016 and has held it in 12 quarters since. The position peaked at $4.71M in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Meadow Creek Investment Management held 1,632 shares of Nektar Therapeutics worth $446K as of Q3 2019.
  • Meadow Creek Investment Management bought 230 Nektar Therapeutics shares in Q3 2019, an estimated $84.3K.
  • Nektar Therapeutics made up 0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #761 holding.
  • Meadow Creek Investment Management first reported a position in Nektar Therapeutics in Q4 2016 and has held it in 12 quarters since.
  • Meadow Creek Investment Management's Nektar Therapeutics position peaked at $4.71M in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.